St. Jude Children’s Research Hospital shed light on what drives this metabolic disease and provides clues to targeted treatment with pantazines.
St. Jude scientists have revealed a previously unknown role for CTCF, a pivotal transcription regulator linked to cancer.
St. Jude scientists detail how inflammasomes act as integral components of mega-cell death complexes called PANoptosomes for host defense in live viral and bacterial infections.
NCI-designated cancer centers, AACI members and other cancer centers and medical groups endorse HPV vaccination and cancer screening to eliminate cancers caused by the virus.
St. Jude and the International Society of Paediatric Oncology report results from the Global Registry of COVID-19 and Childhood Cancer.
St. Jude show that protein structures obtained from cryogenic (frozen) techniques can lead to incorrect or missing information and throw off computational models.
St. Jude Children’s Research Hospital scientists have created a model of the rare pediatric eye cancer that more closely mimics the biology of patient tumors.
St. Jude have uncovered how the body generates protective fetal hemoglobin against sickle cell disease and beta thalassemia.
Measures proposed to address decline in adolescent vaccination associated with the COVID-19 pandemic.
Newly created position will oversee multiple departments and campus expansion.
Vincristine and dexamethasone pulses can be safely eliminated from low-risk acute lymphoblastic leukemia treatment.
St. Jude Children’s Research Hospital study highlights the power of comprehensive whole genome, whole exome and RNA sequencing to better understand and treat each patient’s cancer.
St. Jude scientists study how phase separation begins on a microsecond time scale, showing how the earliest events with individual molecules impact assembly speed.
A collaboration led by
St. Jude Children’s Research Hospital, Shanghai Children’s Medical Center and others revealed how thiopurines produce mutations that lead to multi-drug resistant leukemia and relapse.
St. Jude Children’s Research Hospital scientists have shown that frailty contributes to neurocognitive decline in young adult survivors of childhood cancer.
William L. “Bill” Greene, PharmD, chief pharmaceutical officer, to receive the 2021 Shelby Rhinehart Public Service Lifetime Achievement Award.
St. Jude Children’s scientists have used smFRET and cyro-EM to capture structures of a biologic process through research that has implications for antibiotic development.
A metabolic control pathway that regulates T follicular helper cells offers targets for drugs to stimulate the adaptive immune response.
St. Jude and international collaborators have shown that the enzyme NUDT15 metabolizes ganciclovir and acyclovir, with genetic variants in this gene affecting how patients respond to these drugs.
St. Jude Children’s Research Hospital scientists created a registry for molecular analysis of pediatric melanoma that provides insight into treatment.
A pair of papers from
St. Jude Children’s Research Hospital shows ubiquitination is needed for disassembly of stress granules, which are linked to neurodegenerative diseases.
Research led by
St. Jude and the Munich Leukemia Laboratory highlights molecular analysis as an approach to improve classification and diagnosis of acute leukemia.
Enzyme LRRK2 is a biological switch whose mutation generates abnormal proteins in Parkinson’s patients.
Grief and bereavement expert with years of building social work programs in academia will direct a growing program at
St. Jude Children’s Research Hospital provides the first gene therapy manufacturing and distribution cost report for hemophilia B.
St. Jude Children’s Research Hospital will present their original research and share their expertise at the American Society of Clinical Oncology (ASCO) annual meeting.
The COVID-19 pandemic has interrupted delivery of key health services for children and adolescents, including HPV vaccination for cancer prevention.
St. Jude director of Center of Excellence for Data Driven Discovery named a fellow of British medical association.
St. Jude scientists have developed a highly efficient method to address a major challenge in biology—identifying the genetic ‘switches’ that regulate gene expression.
St. Jude COVID-19 screening and vaccination program for employees offers early evidence that vaccine protects against asymptomatic infection, which has fueled the pandemic.
Centers of Excellence for Influenza Research and Response at
St. Jude earns nearly $9 million in funding.
Six-year plan to invest $11.5 billion with donor support to accelerate research and treatment worldwide.
St. Jude findings highlight genomic analysis as a tool to extend risk-directed therapy and improve outcomes for children with the most common pediatric cancer.
Results from a collaborative multi-site clinical trial show the success of adding brentuximab vedotin, reducing radiation.
Martine Roussel, Ph.D., has been elected to the 2021 Class of Fellows of the American Association for Cancer Research.
St. Jude Children’s Research Hospital are learning more about what the molecular groups of a rare pediatric brain tumor mean for clinical care.
St. Jude scientists have been selected for an international collaborative research effort to advance treatment for some leading causes of childhood cancer death.
An international research team has identified clinical factors associated with the risk of central nervous system relapse in patients with the most common childhood cancer.
Five-year grant will aid in the study of mechanisms underlying neurodegenerative diseases like ALS.
St. Jude is dedicating staff and resources to focus on the prevention of human papillomavirus (HPV)-related cancers around the world through HPV vaccine awareness programming.
Organization details plan to eliminate new HIV infections in Memphis by 2030.
Discovery of a metabolic pathways that inhibit memory T cell production has potential for enhancing the immune system’s ability to fight infections and cancers.
St. Jude has discovered a mechanism that tumors use to switch on protective regulatory T cells, raising the potential for drug treatments that render tumors more vulnerable to cancer immunotherapy.
The project will expand and enhance data collection in low- and middle-income countries to support the global push to advance childhood cancer survival.
Research from scientists at
St. Jude Children’s Research Hospital found mutations up to two years before cancer developed, showing an opportunity for early interventions.
New Zealand’s experience during the first wave of COVID-19 suggests nonpharmaceutical interventions should be considered to control severe viral respiratory outbreaks in the future.
St. Jude Children’s Research Hospital scientists have created a CAR-T cell receptor designed to improve the effectiveness of immunotherapy for treatment of solid tumors.
A pair of research papers from
St. Jude report on a medulloblastoma clinical trial that provides insights to guide treatment and shed light on relapsed disease.
St. Jude have revealed a potential treatment for T Cell ALL using a method that has implications for how cancer therapies are identified in the future.
St. Jude Children’s Research Hospital have created a computational tool for inferring gene promoter activity and expression using DNA methylation data.
St. Jude scientists created a visualization tool to help investigators worldwide harness the scientific and clinical potential of genomic data.
St. Jude scientists created the largest cloud-based genomic resource for pediatric cancer and a data-sharing model to accelerate life-saving research.